Cerebrospinal fluid ratios with Aβ42 predict preclinical brain β‐amyloid accumulation
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Introduction: Biomarkers are urgently needed for the critical yet understudied preclinical stage of Alzheimer's disease (AD). Methods: Cerebrospinal fluid (CSF) collection, [C‐11]Pittsburgh compound B (PiB) amyloid imaging, and magnetic resonance imaging were acquired in 104 cognitively healthy adults enriched with risk for sporadic AD. Image‐derived cerebral β‐amyloid (Aβ) burden, measured concurrently and longitudinally, was regressed on CSF measures of Aβ, neural injury, and inflammation, as well as ratios with Aβ 42. Linear mixed‐effects regression was used to model the effect of the CSF measures that predicted longitudinal brain amyloid accumulation on longitudinal cognitive decline, measured by memory test scores. Results: At baseline, Aβ 42/Aβ 40 and all CSF ratios to Aβ 42 were associated with PiB binding in AD‐vulnerable regions. Longitudinally, Aβ 42/Aβ 40 and ratios of total tau (t‐tau), phosphorylated‐tau (p‐tau), neurofilament light protein, and monocyte chemoattractant protein‐1 to Aβ 42 were associated with increased Aβ deposition over 2 years, predominantly in lateral parietal and temporal cortex. However, these CSF ratios were not significantly associated with cognitive decline, and the effect seems to be largely driven by Aβ 42 in the denominator. Discussion: These results corroborate previous findings that t‐tau/Aβ 42 and p‐tau/Aβ 42 are the strongest candidate biomarkers during the preclinical time frame. They support a framework in which neural injury and amyloid deposition are likely occurring simultaneously. It may be that neurodegenerative processes influence progressive amyloid accumulation, even in the preclinical time frame. CSF biomarkers for nonspecific axonal injury and inflammation may provide more information at more advanced stages of the preclinical time course.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Buckner, R. L., Sepulcre, J., Talukdar, T., Krienen, F. M., Liu, H., Hedden, T., Andrews-Hanna, J. R., Sperling, R. A., & Johnson, K. A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5062-08.2009 · Cited by 2,862
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 1×
“The most widely accepted model of AD etiology proposes that amyloid deposition in the brain is an early and critical step in driving the pathophysiological processes of AD that in turn initiate neurodegeneration, in the form of synaptic failure and neuronal death, and eventual symptom manifestation [1,6,7].”
BackgroundBuckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., Sheline, Y. I., Klunk, W. E., Mathis, C. A., Morris, J. C., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2177-05.2005 · Cited by 2,140 · cited 1×
“[37] (2005) found convergence of five different in vivo imaging methods on the DMN in young adults and older adults with AD, postulating that lifetime cerebral metabolism in the DMN predisposes these cortical regions to AD-related changes including amyloid deposition, metabolic disruption, and atrophy.”
BackgroundCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 1×
“CSF Ab and tau have high diagnostic accuracy for AD [16], but their reliability for the detection of possible preclinical AD is still unclear.”
BackgroundSelf-citationSynaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo
Cirrito, J. R., Yamada, K. A., Finn, M. B., Sloviter, R. S., Bales, K. R., May, P. C., Schoepp, D. D., Paul, S. M., Mennerick, S., & Holtzman, D. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.10.028 · Cited by 1,265 · cited 1×
“It has been suggested that susceptibility to amyloid deposition in these regions may be due to high activity or metabolism [32–34] and relatively greater extent of”
BackgroundInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · cited 1×
“Similarly, studies have shown that combinations of tau and Ab42 improve sensitivity and specificity [5,41,42], predict subjective cognitive decline [43], and predict conversion from a clinical dementia rating of 0 (cognitively normal) to 1 (mild dementia; [44]) and from mild cognitive impairment to AD [45].”
Fjell, A. M., McEvoy, L., Holland, D., Dale, A. M., & Walhovd, K. B. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.004 · Cited by 799 · cited 1×
“neuroplasticity over the life span [35,36].”
The case for rejecting the amyloid cascade hypothesis
Herrup, K. (2015) · Nature Neuroscience · doi:10.1038/nn.4017 · Cited by 768 · cited 1×
“Increasing evidence suggests that amyloid may be necessary—although even this is contested by some [8]—but not sufficient for developing AD [6,8–11].”
Background
Cited by
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Self-citationAshton, N. J., Janelidze, S., Mattsson-Carlgren, N., Binette, A. P., Strandberg, O., Brum, W. S., Karikari, T. K., González-Ortiz, F., Di Molfetta, G., Meda, F. J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02074-w · Cited by 436
Self-citationThe Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions
Johnson, S. C., Koscik, R. L., Jonaitis, E. M., Clark, L. R., Mueller, K. D., Berman, S. E., Bendlin, B. B., Engelman, C. D., Okonkwo, O. C., Hogan, K. J., et al. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.11.007 · Cited by 316
Self-citationLewczuk, P., Riederer, P., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramirez, A., Parnetti, L., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 307
Self-citationCerebrospinal Fluid Aβ 42/40 Corresponds Better than Aβ 42 to Amyloid PET in Alzheimer’s Disease
Lewczuk, P., Matzen, A., Blennow, K., Parnetti, L., Molinuevo, J. L., Eusebi, P., Kornhuber, J., Morris, J. C., & Fagan, A. M. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160722 · Cited by 253
Self-citation
Metadata
- Authors
- Racine, A. M., Koscik, R. L., Nicholas, C. R., Clark, L. R., Okonkwo, O. C., Oh, J. M., Hillmer, A. T., Murali, D., Barnhart, T. E., Betthauser, T. J., Gallagher, C. L., Rowley, H. A., Dowling, N. M., Asthana, S., Bendlin, B. B., Blennow, K., Zetterberg, H., Carlsson, C. M., Christian, B. T., & Johnson, S. C.
- Venue
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Publisher
- Wiley
- Published
- 2015-12-20
- Volume
- 2
- Issue
- 1
- Pages
- 27-38
- ISSN
- 2352-8729 (ISSN-L)
- OpenAlex
- W2197209689
- Cited by
- 58
- References
- 20
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cerebrospinal fluid ratios with Aβ42 predict preclinical brain β‐amyloid accumulation. https://app.cochat.ai/papers/10.1016/j.dadm.2015.11.006
- The paper
- Racine, A. M., Koscik, R. L., Nicholas, C. R., Clark, L. R., Okonkwo, O. C., Oh, J. M., Hillmer, A. T., Murali, D., Barnhart, T. E., Betthauser, T. J., Gallagher, C. L., Rowley, H. A., Dowling, N. M., Asthana, S., Bendlin, B. B., Blennow, K., Zetterberg, H., Carlsson, C. M., Christian, B. T., & Johnson, S. C. (2016). Cerebrospinal fluid ratios with Aβ42 predict preclinical brain β‐amyloid accumulation. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. https://doi.org/10.1016/j.dadm.2015.11.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.